ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Lantern Pharma Inc

Lantern Pharma Inc (LTRN)

3.40
-0.02
( -0.58% )
Updated: 11:04:42

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
3.40
Bid
3.31
Ask
3.40
Volume
76,053
3.07 Day's Range 3.41
2.79 52 Week Range 11.99
Market Cap
Previous Close
3.42
Open
3.41
Last Trade
1
@
3.272
Last Trade Time
11:03:16
Financial Volume
$ 243,511
VWAP
3.2019
Average Volume (3m)
57,325
Shares Outstanding
10,784,725
Dividend Yield
-
PE Ratio
-2.24
Earnings Per Share (EPS)
-1.48
Revenue
-
Net Profit
-15.96M

About Lantern Pharma Inc

Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline o... Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eight therapeutic targets. Its A.I. platform, known as RADR, includes more than 18 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Lantern Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LTRN. The last closing price for Lantern Pharma was $3.42. Over the last year, Lantern Pharma shares have traded in a share price range of $ 2.79 to $ 11.99.

Lantern Pharma currently has 10,784,725 shares outstanding. The market capitalization of Lantern Pharma is $36.88 million. Lantern Pharma has a price to earnings ratio (PE ratio) of -2.24.

LTRN Latest News

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Multiple clinical trial sites across Taiwan are actively screening patients, following successful site initiation visits. Expansion into Taiwan is particularly significant as over 50% of lung...

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

This is the second Fast Track Designation granted to LP-184 in 2024, following the designation for Glioblastoma (GBM) announced in October 2024. Fast Track Designation for LP-184 recognizes TNBC...

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

The Phase 1b clinical trial design presented at SNO2024 combines LP-184 (STAR-001) with spironolactone to potentially enhance therapeutic response in recurrent glioblastoma (GBM) patients...

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Ten clinical trial sites across Japan and Taiwan are actively screening patients, with additional sites expected to also begin patient enrollment in the coming months U.S. clinical sites...

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Lantern is advancing three AI-guided precision-oncology drug candidates in active Phase 1 and Phase 2 clinical trials, while evaluating additional ADC-based preclinical molecules for...

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Starlight Therapeutics, a wholly-owned subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), formed to develop transformative CNS cancer treatments with AI-powered innovation, announced today the...

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

Webcast to be held Thursday, November 7th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”...

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.237.255520504733.173.973.01862083.34422401CS
40.144.294478527613.264.883.01791443.61315724CS
12-0.32-8.602150537633.724.882.79573253.46447843CS
26-1.36-28.57142857144.765.12.79529683.77625568CS
52-0.84-19.81132075474.2411.992.791249206.30130508CS
156-4.11-54.72703062587.5111.992.38676425.88043432CS
260-11.76-77.572559366815.1624.842.38745469.47119831CS

LTRN - Frequently Asked Questions (FAQ)

What is the current Lantern Pharma share price?
The current share price of Lantern Pharma is $ 3.40
How many Lantern Pharma shares are in issue?
Lantern Pharma has 10,784,725 shares in issue
What is the market cap of Lantern Pharma?
The market capitalisation of Lantern Pharma is USD 36.88M
What is the 1 year trading range for Lantern Pharma share price?
Lantern Pharma has traded in the range of $ 2.79 to $ 11.99 during the past year
What is the PE ratio of Lantern Pharma?
The price to earnings ratio of Lantern Pharma is -2.24
What is the reporting currency for Lantern Pharma?
Lantern Pharma reports financial results in USD
What is the latest annual profit for Lantern Pharma?
The latest annual profit of Lantern Pharma is USD -15.96M
What is the registered address of Lantern Pharma?
The registered address for Lantern Pharma is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
Which industry sector does Lantern Pharma operate in?
Lantern Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WATTEnergous Corporation
$ 1.66
(303.70%)
147.46M
NXUNXU Inc
$ 0.9479
(289.44%)
283.29M
INTZIntrusion Inc
$ 5.60
(159.26%)
101.64M
CYNCYNGN Inc
$ 1.36
(116.59%)
27.18M
VINCVincerx Inc
$ 0.3925
(102.32%)
258.7M
ABPAbpro Holdings Inc
$ 2.3076
(-48.61%)
815.51k
TRAWTraws Pharma Inc
$ 8.2234
(-38.72%)
769.8k
LITMSnow Lake Resources Ltd
$ 1.185
(-25.94%)
38.83M
BITSGlobal X Blockchain and Bitcoin Stratagy ETF
$ 66.34
(-25.01%)
7.08k
TOIIWOncology Institute Inc
$ 0.0084
(-22.94%)
75.47k
NXUNXU Inc
$ 0.9483
(289.61%)
283.3M
VINCVincerx Inc
$ 0.3922
(102.16%)
258.71M
WATTEnergous Corporation
$ 1.65
(301.26%)
147.47M
XTIAXTI Aerospace Inc
$ 0.0401
(1.52%)
145.31M
INTZIntrusion Inc
$ 5.5932
(158.94%)
101.64M

LTRN Discussion

View Posts
Monksdream Monksdream 4 months ago
LTRN under $5
👍️0
anabu9 anabu9 4 months ago
Finally an UP day. 'hope institutions will see this nugget soon
👍️0
FALCON1 FALCON1 5 months ago
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation
👍️0
dinogreeves dinogreeves 8 months ago
Nice drop
🕳️ 1 🪦 1 ⚰️ 1
Monksdream Monksdream 8 months ago
LTRN under $10
👍️0
Monksdream Monksdream 9 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️0
dinogreeves dinogreeves 9 months ago
Monk, take a look at ANV*S. Data is due sometime in April, Parkinsons and Alzheimers. They just did a private placement on Friday and another one today to an institutional investor. "Subject to Certain Conditions". Looks like April is go time.
👍️0
dinogreeves dinogreeves 9 months ago
I think we can revisit the high again hopefully this week. Been here since 7.20
🖕🏻 1
spartex spartex 9 months ago
10-K filing, Earnings Webcast, Presentation in link below from LTRN company website


https://ir.lanternpharma.com/news-events/press-releases/detail/150/lantern-pharma-reports-fourth-quarter-fiscal-year-2023
👍️0
Monksdream Monksdream 9 months ago
LTRN new 52 hi
👍️0
dinogreeves dinogreeves 9 months ago
Another very good day today.
👍️0
Monksdream Monksdream 9 months ago
LTRN 10Q due 3/18
👍️0
dinogreeves dinogreeves 9 months ago
Very good move on Friday.
🪦 1 ☠️ 1 ⚰️ 1 ⚱️ 1
dinogreeves dinogreeves 10 months ago
This company will see 3 digit dollars, how soon? All depends on just one science behind their Artificial Intelligence to decode one cancer indication the rest will be history.
👍️0
dinogreeves dinogreeves 10 months ago
This is going to have one heck of a run.
👍️0
Tremors! Tremors! 10 months ago
Will they break 10.00!??
👍️0
Roily23 Roily23 10 months ago
👍️0
Roily23 Roily23 10 months ago
AI is the next .com and AI's application in medicine and pharma will be a game changer.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
👍️0